missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CTLA-4 Recombinant Human Monoclonal Antibody (12E8)
Human Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA560737
This item is not returnable.
View return policy
Description
CTLA-4 Recombinant Monoclonal Antibody for ELISA
CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) is a CD28-family receptor expressed on mainly CD4+ T cells. It binds the same ligands as CD28 (CD80 and CD86 on B cells and dendritic cells), but with higher affinity than CD28. However, in contrast to CD28 which enhances cell function when bound at the same time as the T cell receptor, CTLA4 inhbits the T cell and prevents it from functioning. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function.
Specifications
| CTLA-4 | |
| Recombinant Monoclonal | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.03% ProClin 300; pH 7.4 | |
| P16410 | |
| CTLA4 | |
| Recombinant Human proetin L protein. | |
| 100 μL | |
| Primary | |
| Human, Bacteria | |
| Antibody | |
| IgG1 |
| ELISA | |
| 12E8 | |
| Unconjugated | |
| CTLA4 | |
| ALPS5; CD; CD152; CD152 antigen; CD152 isoform; CD152 protein; CD152 protein precursor; celiac disease 3; CELIAC3; Ctla4; CTLA-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; cytotoxic T-lymphocyte associated protein 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; EGK_04712; GRD4; GSE; ICOS; IDDM12; insulin-dependent diabetes mellitus 12; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; Ly-56; sCTLA4; soluble form; transmembrane form | |
| Human | |
| Affinity chromatography | |
| RUO | |
| 1493 | |
| -20°C or -80°C if preferred | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction